Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2021 2
2022 5
2023 2
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Results by year

Filters applied: . Clear all
Page 1
Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: A Randomized Clinical Trial.
Al Kaabi N, Zhang Y, Xia S, Yang Y, Al Qahtani MM, Abdulrazzaq N, Al Nusair M, Hassany M, Jawad JS, Abdalla J, Hussein SE, Al Mazrouei SK, Al Karam M, Li X, Yang X, Wang W, Lai B, Chen W, Huang S, Wang Q, Yang T, Liu Y, Ma R, Hussain ZM, Khan T, Saifuddin Fasihuddin M, You W, Xie Z, Zhao Y, Jiang Z, Zhao G, Zhang Y, Mahmoud S, ElTantawy I, Xiao P, Koshy A, Zaher WA, Wang H, Duan K, Pan A, Yang X. Al Kaabi N, et al. Among authors: eltantawy i. JAMA. 2021 Jul 6;326(1):35-45. doi: 10.1001/jama.2021.8565. JAMA. 2021. PMID: 34037666 Free PMC article. Clinical Trial.
Safety and immunogenicity of the NVX-CoV2373 vaccine as a booster in adults previously vaccinated with the BBIBP-CorV vaccine.
Toback S, Marchese AM, Warren B, Ayman S, Zarkovic S, ElTantawy I, Mallory RM, Rousculp M, Almarzooqi F, Piechowski-Jozwiak B, Bonilla MF, Bakkour AE, Hussein SE, Al Kaabi N. Toback S, et al. Among authors: eltantawy i. Vaccine. 2024 Mar 7;42(7):1777-1784. doi: 10.1016/j.vaccine.2024.02.037. Epub 2024 Feb 15. Vaccine. 2024. PMID: 38365482 Free article. Clinical Trial.
Effectiveness of BBIBP-CorV vaccine against severe outcomes of COVID-19 in Abu Dhabi, United Arab Emirates.
Al Kaabi N, Oulhaj A, Ganesan S, Al Hosani FI, Najim O, Ibrahim H, Acuna J, Alsuwaidi AR, Kamour AM, Alzaabi A, Al Shehhi BA, Al Safar H, Hussein SE, Abdalla JS, Al Mansoori DSN, Al Hammadi AAK, Amari MA, Al Romaithi AK, Weber S, Elavalli S, Eltantawy I, Alghaithi NK, Al Azazi JN, Holt SG, Mostafa M, Halwani R, Khalak H, Elamin W, Beiram R, Zaher W. Al Kaabi N, et al. Among authors: eltantawy i. Nat Commun. 2022 Jun 9;13(1):3215. doi: 10.1038/s41467-022-30835-1. Nat Commun. 2022. PMID: 35680857 Free PMC article.
Immunogenicity and safety of NVSI-06-07 as a heterologous booster after priming with BBIBP-CorV: a phase 2 trial.
Kaabi NA, Yang YK, Zhang J, Xu K, Liang Y, Kang Y, Su JG, Yang T, Hussein S, ElDein MS, Shao S, Yang SS, Lei W, Gao XJ, Jiang Z, Wang H, Li M, Mekki HM, Zaher W, Mahmoud S, Zhang X, Qu C, Liu DY, Zhang J, Yang M, Eltantawy I, Xiao P, Wang ZN, Yin JL, Mao XY, Zhang J, Liu N, Shen FJ, Qu L, Zhang YT, Yang XM, Wu G, Li QM. Kaabi NA, et al. Among authors: eltantawy i. Signal Transduct Target Ther. 2022 Jun 6;7(1):172. doi: 10.1038/s41392-022-00984-2. Signal Transduct Target Ther. 2022. PMID: 35665745 Free PMC article. Clinical Trial.
Safety and immunogenicity of a hybrid-type vaccine booster in BBIBP-CorV recipients in a randomized phase 2 trial.
Kaabi NA, Yang YK, Du LF, Xu K, Shao S, Liang Y, Kang Y, Su JG, Zhang J, Yang T, Hussein S, ElDein MS, Yang SS, Lei W, Gao XJ, Jiang Z, Cong X, Tan Y, Wang H, Li M, Mekki HM, Zaher W, Mahmoud S, Zhang X, Qu C, Liu DY, Zhang J, Yang M, Eltantawy I, Hou JW, Lei ZH, Xiao P, Wang ZN, Yin JL, Mao XY, Zhang J, Qu L, Zhang YT, Yang XM, Wu G, Li QM. Kaabi NA, et al. Among authors: eltantawy i. Nat Commun. 2022 Jun 27;13(1):3654. doi: 10.1038/s41467-022-31379-0. Nat Commun. 2022. PMID: 35760812 Free PMC article. Clinical Trial.
Safety and immunogenicity of a mosaic vaccine booster against Omicron and other SARS-CoV-2 variants: a randomized phase 2 trial.
Kaabi NA, Yang YK, Liang Y, Xu K, Zhang XF, Kang Y, Jin YQ, Hou JW, Zhang J, Yang T, Hussein S, ElDein MS, Lei ZH, Zhang H, Shao S, Liu ZM, Liu N, Zheng X, Su JG, Yang SS, Cong X, Tan Y, Lei W, Gao XJ, Jiang Z, Wang H, Li M, Mekki HM, Zaher W, Mahmoud S, Zhang X, Qu C, Liu DY, Zhang J, Yang M, Eltantawy I, Xiao P, Shen FJ, Wu JJ, Han ZB, Du LF, Tang F, Chen S, Ma ZJ, Zheng F, Hou YN, Li XY, Li X, Wang ZN, Yin JL, Mao XY, Zhang J, Qu L, Zhang YT, Yang XM, Wu G, Li QM. Kaabi NA, et al. Among authors: eltantawy i. Signal Transduct Target Ther. 2023 Jan 3;8(1):20. doi: 10.1038/s41392-022-01295-2. Signal Transduct Target Ther. 2023. PMID: 36596779 Free PMC article. Clinical Trial.
The incidence of COVID-19 infection following emergency use authorization of BBIBP-CORV inactivated vaccine in frontline workers in the United Arab Emirates.
Al Kaabi N, Oulhaj A, Al Hosani FI, Al Mazrouei S, Najim O, Hussein SE, Abdalla JS, Fasihuddin MS, Hassan AA, Elghazali G, Al Rumaithi A, Al Azazi J, Weber S, Beiram R, Parekh KA, Sheek-Hussein M, Yang Y, Xiaoming Y, Quliang J, Eltantawy I, Mahmoud S, Koshy A, Xiao P, Ganesan S, Elamin W, Zaher W. Al Kaabi N, et al. Among authors: eltantawy i. Sci Rep. 2022 Jan 11;12(1):490. doi: 10.1038/s41598-021-04244-1. Sci Rep. 2022. PMID: 35017530 Free PMC article.
Efficacy and Safety of a Booster Vaccination with Two Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: Results of a Double-Blind, Randomized, Placebo-Controlled, Phase 3 Trial in Abu Dhabi.
Al Kaabi N, Yang Y, Eldin Hussein S, Yang T, Abdalla J, Wang H, Lou Z, Chinese Center For Disease Control And Prevention, Bakkour A, Arafat A, China National Biotec Group Company Limited, Jiang Z, Tian Y, National Engineering Technology Research Center For Combined Vaccines Wuhan Institute Of Biological Products Co Ltd, Beijing Institute Of Biological Products Company Limited, Xiao P, Zaher W, Eltantawy I, Wang C, Xu G, Zhang Y, Yang X. Al Kaabi N, et al. Among authors: eltantawy i. Vaccines (Basel). 2023 Jan 30;11(2):299. doi: 10.3390/vaccines11020299. Vaccines (Basel). 2023. PMID: 36851177 Free PMC article.